Journal of Cancer Research and Therapeutics Close
 

Figure 4: Changes in CA125 and neuron-specific enolase. (a) Changes in CA125 (normal range within 0 ~45 U/ml). (b) Changes in neuron-specific enolase (normal range within 0 ~16.3 ng/ml) 2019.07.13: Baseline before therapy. 2019.09.07, 2019.10.05: After 1 and 2 cycles of GN. 2019.11.21: Before VEC and apatinib administration. 2019.12.19, 2020.01.17, 2020.03.14, 2020.04.20, 2020.06.06, 2020.07.30: After 1, 2, 3, 4, 5 and 6 cycles of VEC and apatinib. Ps: GN: Gemcitabine and nedaplatin. VEC: Vincristine, epirubicin, and cyclophosphamide

Figure 4: Changes in CA125 and neuron-specific enolase. (a) Changes in CA125 (normal range within 0 ~45 U/ml). (b) Changes in neuron-specific enolase (normal range within 0 ~16.3 ng/ml) 2019.07.13: Baseline before therapy. 2019.09.07, 2019.10.05: After 1 and 2 cycles of GN. 2019.11.21: Before VEC and apatinib administration. 2019.12.19, 2020.01.17, 2020.03.14, 2020.04.20, 2020.06.06, 2020.07.30: After 1, 2, 3, 4, 5 and 6 cycles of VEC and apatinib. Ps: GN: Gemcitabine and nedaplatin. VEC: Vincristine, epirubicin, and cyclophosphamide